MONROE TOWNSHIP, N.J., Nov. 26, 2017 /PRNewswire/ — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today key achievements that further position the company to afford patients and physicians greater choice when it comes to their imaging needs. The announcement sets the stage for the company’s presence at the Radiological Society of North America (RSNA) Annual Meeting (South Hall A Booth# 1911), which will highlight the breadth, depth and ongoing advancement of its diagnostic imaging solutions and services portfolio.
Bracco Diagnostics Inc. Showcases Continued Commitment to Product Advancement at the 2017 Radiological Society of North America (RSNA) Annual Meeting
“We’ve remained relentless in our pursuit to consistently deliver diagnostic imaging solutions and services that focus on efficacy, safety, quality and cost effectiveness and are aligned with the distinct needs of patients and physicians,” said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “These milestones, as well as our successful track record of bringing innovative products and solutions to the diagnostic imaging market, demonstrate our unwavering dedication to this end.”
The following is a review of the Bracco Diagnostics Inc. major achievements for 2017:
The Bracco Group’s 90th anniversary. The success and growth of a family-run company stems from its continued commitment to fully understand the needs of customers and patients they serve through the changing dynamics of the life sciences landscape. Click here to read about how the company commemorated this hallmark event. The celebration of the 25th anniversary of its launch of the first macrocyclic gadolinium magnetic resonance imaging (MRI) contrast agent approved in the United States. The FDA approval for its contrast enhanced ultrasound (CEUS) agent for use in ultrasonography of the urinary tract (voiding ultrasonography) for the evaluation of suspected or known vesicoureteral reflux in pediatric patients. The FDA also removed the contraindication for use of the CEUS agent in patients with cardiac shunts. Bracco offers the only CEUS agent approved for three indications in echocardiography and non-cardiac indications. The launch of its best-in-class contrast media injector technology through its SmartInjectCT solution aimed at improving the quality of patient care and cost effectiveness of CT procedures. The FDA approval for four additional barium-based products. One product to visualize the gastrointestinal tract in adult and pediatric